Drug
Tividenofusp Alfa
Tividenofusp Alfa: highest development phase Phase 2/3, developed by Denali Therapeutics. 3 trial records tracked on RxWires.
- Highest phase
- Phase 2/3
- Developer
- Denali Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| tividenofusp alfa NCT05371613 | Phase 2/3 | Mucopolysaccharidosis II |
| tividenofusp alfa NCT06075537 | Phase 2/3 | Mucopolysaccharidosis II |
| tividenofusp alfa NCT04251026 | Phase 1/2 | Mucopolysaccharidosis II |
Latest
No recent events.
Follow Tividenofusp Alfa on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.